Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Booth S, Plaschkes H, Kirkwood AA, Gibb A, Horgan P, Higham C, Oladipo JM, Browning J, Khan U, Tseu B, Chen L, Willan J, Wolf J, Gunawan A, Fields P, Ebsworth T, Lown R, Gordon-Walker D, Shah N, Linton KM, Collins GP, Kothari J, Hildyard C, Eyre TA. Booth S, et al. Among authors: fields p. Blood Adv. 2020 Sep 22;4(18):4337-4346. doi: 10.1182/bloodadvances.2020002553. Blood Adv. 2020. PMID: 32915975 Free PMC article.
A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.
Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K. Kassam S, et al. Among authors: fields p. Leuk Lymphoma. 2013 Sep;54(9):1921-7. doi: 10.3109/10428194.2012.754024. Epub 2013 Jan 4. Leuk Lymphoma. 2013. PMID: 23206228
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D. Fields PA, et al. J Clin Oncol. 2014 Feb 1;32(4):282-7. doi: 10.1200/JCO.2013.49.7586. Epub 2013 Nov 12. J Clin Oncol. 2014. PMID: 24220559 Clinical Trial.
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S. Dhanapal V, et al. Among authors: fields p. Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28093003
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: fields p. J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11. J Intern Med. 2019. PMID: 30811713 Free article.
453 results